Heart abnormalities in parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: A treatment-blinded echocardiographic study

Journal of Heart Valve Disease

Volumn 18, Issue 4, 2009, Pages 463-469

  Rasmussen, Vibeke G ^a   Poulsen, Steen H ^a   Dupont, Erik ^a   Østergaard, Karen ^a   Safikhany, Gholamhossein ^a   Egeblad, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; ECHOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; MITRAL VALVE; PARKINSON DISEASE; PULMONARY HYPERTENSION; VALVULAR HEART DISEASE;

AGED; DOPAMINE AGONISTS; ERGOT ALKALOIDS; FEMALE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MITRAL VALVE; PARKINSON DISEASE;

EID: 79551608757     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and parkinson disease: An observational study and meta-analysis. Arch Neurol 2007; 64:1721-1726
2. Dewey RB, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007; 64:377-380
3. Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A readerblinded monocenter echocardiography study. Mov Disord 2007; 22:234-238
4. Kenangil G, Ozekmekci S, Koldas L, Sahin T, Erginoz E. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg 2007; 109: 350-353
5. Kim JY, Chung EJ, Park SW, Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006; 21:1261-1264
6. Peralta C, Wolf E, Alber H, et al. Valvular heart dis- ease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 2006; 21: 1109-1113
7. Rasmussen VG, Poulsen SH, Dupont E, Ostergaard K, Safikhany G, Egeblad H. Heart valve disease associated with treatment with ergot-derived dopamine agonists: A clinical and echocardiographic study of patients with Parkinson's disease. J Intern Med 2008; 263:90-98
8. Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. J Neurol 2007; 254:1575-1578
9. Van CG, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179-1183
10. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology 2006; 67:1225-1229
11. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39-46
12. Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: Pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 2007; 28:2156-2162
13. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000; 57:75-81
14. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4- Methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63:1223-1229
15. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB, Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63:301-304
16. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19:656-662
17. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777-802
18. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997; 46:1061-1066
19. Gardin JM, Weissman NJ, Leung C, et al. Clinical and echocardiography follow-up of patients previously treated with dexfenfluramine or phenter-mine/fenfluramine. JAMA 2001; 286:2011-2014
20. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001; 134:261-266
21. Weissman NJ, Panza J A, Tighe JF, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:267-273
22. Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006; 13:1049-1065
23. Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006; 125:152-164